Efficacy and Safety of IQP-VV-102 in Weight Management

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of IQP- AK-102 in Reducing Body Weight

NCT01905956

Weight Loss

COMPLETED PHASE3

Benefit and Tolerability of IQP-LU-104 in Weight Loss

NCT03888911

Overweight Obesity

COMPLETED NA

Benefit and Tolerability of IQP-AE-103 in Weight Loss

NCT03058367

Overweight Obesity

COMPLETED NA

Safety and Efficacy of IQP-AK-102 in Reducing Appetite

NCT02041754

Weight Loss Appetite Modulation (Focus of Study)

COMPLETED PHASE3

DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects

NCT04086797

Overweight Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IQP-VV-102

2 tablets twice a day

Group Type ACTIVE_COMPARATOR

IQP-VV-102

Intervention Type DIETARY_SUPPLEMENT

Placebo

2 tablets twice a day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IQP-VV-102

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 60 years
* 25 kg/m2 ≤ BMI ≤ 35 kg/m2
* Written informed consent

Exclusion Criteria

* Known sensitivity to sources of the active ingredients and excipients
* Pregnancy or nursing
* Inability to comply with study requirements, e.g. due to language difficulties
* Participation in another study during the last 30 days of the screening visit

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes